Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

Shannon A Miller1, Erin L St Onge2, J Roger Accardi31Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA; 2University of Florida College of Pharmacy, Orlando Campus, Florida, USA; 3Accardi Clinical Pharmacy, Orange City, Florida, USAAbstract: The American...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shannon A Miller, Erin L St Onge, J Roger Accardi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/4a731fcf1dd7442caac8af79d6fa60ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a731fcf1dd7442caac8af79d6fa60ab
record_format	dspace
spelling	oai:doaj.org-article:4a731fcf1dd7442caac8af79d6fa60ab2021-12-02T06:08:59ZSitagliptin as combination therapy in the treatment of type 2 diabetes mellitus1178-7007https://doaj.org/article/4a731fcf1dd7442caac8af79d6fa60ab2009-05-01T00:00:00Zhttp://www.dovepress.com/sitagliptin-as-combination-therapy-in-the-treatment-of-type-2-diabetes-a3128https://doaj.org/toc/1178-7007Shannon A Miller1, Erin L St Onge2, J Roger Accardi31Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA; 2University of Florida College of Pharmacy, Orlando Campus, Florida, USA; 3Accardi Clinical Pharmacy, Orange City, Florida, USAAbstract: The American Diabetes Association and The European Association for the Study of Diabetes recommend metformin as the initial agent of choice in the treatment of type 2 diabetes mellitus. Unfortunately, most patients require multiple medications to obtain glycemic control. One of the newest additions to the antidiabetic armamentarium is the class of drugs known as dipeptidyl-peptidase IV (DPP-IV) inhibitors. This novel approach focuses on harnessing the beneficial effects of GLP-1, an incretin hormone released from the gut postprandially. The first DPP-IV inhibitor approved in the United States was sitagliptin. It has been studied in both monotherapy and combination therapy. Combination studies with metformin realize a hemoglobin A1c reduction of 0.65%&ndash;1.1%. The combination of the two has a modest positive effect on body weight with the convenience of an oral route of administration. It has also been shown to be highly tolerable, efficacious and with little risk of hypoglycemia. This review will focus on combination therapy with sitagliptin with emphasis on combination with metformin. Keywords: DPP-IV inhibitor, sitagliptin, metformin, type 2 diabetes, incretins Shannon A MillerErin L St OngeJ Roger AccardiDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 23-30 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Shannon A Miller Erin L St Onge J Roger Accardi Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
description	Shannon A Miller1, Erin L St Onge2, J Roger Accardi31Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA; 2University of Florida College of Pharmacy, Orlando Campus, Florida, USA; 3Accardi Clinical Pharmacy, Orange City, Florida, USAAbstract: The American Diabetes Association and The European Association for the Study of Diabetes recommend metformin as the initial agent of choice in the treatment of type 2 diabetes mellitus. Unfortunately, most patients require multiple medications to obtain glycemic control. One of the newest additions to the antidiabetic armamentarium is the class of drugs known as dipeptidyl-peptidase IV (DPP-IV) inhibitors. This novel approach focuses on harnessing the beneficial effects of GLP-1, an incretin hormone released from the gut postprandially. The first DPP-IV inhibitor approved in the United States was sitagliptin. It has been studied in both monotherapy and combination therapy. Combination studies with metformin realize a hemoglobin A1c reduction of 0.65%&ndash;1.1%. The combination of the two has a modest positive effect on body weight with the convenience of an oral route of administration. It has also been shown to be highly tolerable, efficacious and with little risk of hypoglycemia. This review will focus on combination therapy with sitagliptin with emphasis on combination with metformin. Keywords: DPP-IV inhibitor, sitagliptin, metformin, type 2 diabetes, incretins
format	article
author	Shannon A Miller Erin L St Onge J Roger Accardi
author_facet	Shannon A Miller Erin L St Onge J Roger Accardi
author_sort	Shannon A Miller
title	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
title_short	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
title_full	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
title_fullStr	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
title_full_unstemmed	Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
title_sort	sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/4a731fcf1dd7442caac8af79d6fa60ab
work_keys_str_mv	AT shannonamiller sitagliptinascombinationtherapyinthetreatmentoftype2diabetesmellitus AT erinlstonge sitagliptinascombinationtherapyinthetreatmentoftype2diabetesmellitus AT jrogeraccardi sitagliptinascombinationtherapyinthetreatmentoftype2diabetesmellitus
_version_	1718400048549593088

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

Ejemplares similares